Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Treatment of Leg Fractures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subject who is 18 years of age or older at the time of signing the informed consent.~2. Subject provides an Institutional Review Board (IRB)-approved informed consent. The subject must have the physical and mental capacity to provide informed consent for him/herself.~3. Subject has experienced proximal tibial fracture (OTA Type 41 A-C) or distal tibial fracture (OTA 43 Type A-C) with or without fibular/malleolar involvement (OTA 44 A-C) and are scheduled for ORIF using the EVOS SMALL Plating System.~4. Subject is willing and able to attend all study visits including 1 year post-operative follow-up.~Exclusion Criteria:~1. Subject has contraindications or hypersensitivity to the use of the EVOS SMALL Plating System or its components (316L stainless steel).~2. Subject has a physical condition that, in the opinion of the Investigator, would preclude adequate implant support or retard healing, such as blood supply impairment, insufficient bone quality or quantity, previous infection, obesity, severe bow or gross bony distortion of the tibia, as detailed in the IFU.~3. Subject has, in the opinion of the Investigator, an emotional or neurologic condition that precludes cooperation and compliance with the rehabilitation regimen.~4. Subject is currently in another investigational drug, biologic, or device study or has been treated with an investigational product within the last 30 days.~5. Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Treatment (Type: None): EVOS SMALL PLating System

Based on this trial design, predict the completion outcome and termination type (if applicable).